Critical Analysis: Intra-Cellular Therapies, Inc. v. Controller of Patents (2026:DHC:5394) C.A.(COMM.IPD-PAT) 24/2023 | Delhi High Court | Decided: 06.07.2026 I. Doctrinal Analysis: Novelty and the "Coverage vs. Disclosure" Question A. The genus-species anticipation problem The core novelty dispute was a classic Markush-genus-versus-species-selection issue. The appellant argued that arriving at the claimed species from the generic Formula I of D1/D7 required " multiple selections " among independent variables (R1–R6), and that the Controller impermissibly relied on more than one prior art document to construct a single "closest prior art" novelty attack — a submission with real doctrinal pedigree, since novelty (unlike obviousness) is ordinarily tested against a single prior document read as a whole. The Court's response — invoking AstraZeneca AB and Boehringer Ingelheim v. Vee Excel — collapses the " covered vs. disclosed " dist...
Introduction China has completed the most consequential rewrite of its Trademark Law in over a decade. On June 26, 2026, the 23rd Meeting of the Standing Committee of the Fourteenth National People's Congress adopted a comprehensive revision of the Trademark Law of the People's Republic of China — the fifth amendment since the law was first enacted in 1982, and the first substantive overhaul since the narrow 2019 revision. The revised law, comprising 87 articles across nine chapters (up from 73 articles in eight chapters under the outgoing law), will enter into force on January 1, 2027. Trademarks registered before that date remain valid. For brand owners, in-house counsel, and IP practitioners with China exposure, this is not a routine update. The revision touches registration standards, opposition timelines, well-known mark protection, damages calculations, and — perhaps most significantly — the treatment of bad-faith and speculative filings that have long troubled foreig...